Brief: Fosun Pharma Says Henlius Signs Licensing Agreement With Eisai
05/02/2026 08:41
Feb 5 (Reuters) - Shanghai Fosun Pharmaceutical 600196.SS: SAYS HENLIUS BIOTECH SIGNS LICENSING AGREEMENT WITH EISAI SAYS HENLIUS GRANTS EISAI RIGHTS TO DEVELOP, PRODUCE, COMMERCIALIZE SERPLULIMAB INJECTION Source text Further company coverage: 600196.SS (Reporting by Beijing Newsroom) ((Ethan.Wang@thomsonreuters.com;))
Recent news on Shanghai Henlius Biotech
See all newsBrief: Shanghai Henlius Biotech Says Wenjie Zhang Resigns As Chairman
Brief: Shanghai Henlius Biotech Enters Collaboration And License Agreement With Amberstone Biosciences
Brief: Shanghai Henlius Biotech Says NDA For 120 Mg Biosimilar Denosumab HLX14 Accepted By NMPA
China's Henlius H1 revenue jumps on drug sales, license income
Brief: Shanghai Henlius Biotech Logs HY Profit RMB 430.4 Mln